| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Proton pump
Pantoprazole targets the H⁺/K⁺-ATPase enzyme (proton pump) in the parietal cells of the gastric mucosa. It binds covalently to the enzyme, irreversibly inhibiting its function and blocking the final step of acid secretion. This inhibition affects both basal and stimulated gastric acid secretion regardless of the stimulus. |
|---|---|
| ln Vitro |
In EMT-6 and MCF7 cells, pantoprazole sodium (BY1023 sodium; 1–10,000 μM) raises endosomal pH in a concentration-dependent manner [1]. Pantoprazole sodium has the ability to prevent exosome release. Pantoprazole sodium prevents tumor cells (melanoma, adenocarcinoma, and lymphoma cell lines) from acidifying the extracellular media by blocking V-H+-ATPase activity [2].
In vitro studies show that pantoprazole inhibits tumor cell proliferation, induces apoptosis, and decreases the expression of HIF-1α protein in cancer cells. It affects the intracellular distribution of HIF-1α in SGC-7901 cells, which may contribute to its chemosensitizing effect on cancer cells. The compound also inhibits autophagy and increases the toxicity of docetaxel. |
| ln Vivo |
In MCF-7 xenografts, the combination of pantoprazole sodium (BY1023 sodium; 200 mg/kg; intraperitoneal injection; once weekly for 3 weeks) and doxorubicin considerably prolonged the tumor development delay [1]. Oral pantoprazole sodium (0.3–3 mg/kg) decreases mepizole-induced stimulated acid secretion in acute fistula rats and basal acid secretion in pyloric ligation rats in a dose-dependent manner [4].
Pantoprazole effectively inhibits gastric acid secretion in vivo. It is commonly prescribed for conditions including gastroesophageal reflux disease (GERD), peptic ulcers, and gastritis. The compound’s irreversible inhibition of H⁺/K⁺-ATPase provides prolonged acid suppression with once-daily dosing. |
| Enzyme Assay |
The action of the H+/K(+)-ATPase inhibitors pantoprazole and omeprazole was compared in different in vitro test systems. In gastric membrane vesicles under conditions shown to result in acidification of the vesicle interior, pantoprazole and omeprazole inhibited H+/K(+)-ATPase activity with IC50 values of 6.8 and 2.4 microM, respectively. When intravesicular acidification was reduced by inclusion of imidazole (5 mM), a membrane permeable weak base, the inhibitory action of omeprazole was partially lost (IC50 30 microM) and that of pantoprazole almost completely lost. After incubation for 40 min with pumping membrane vesicles, a half-maximal reduction in intravesicular H+ concentration occurred at pantoprazole and omeprazole concentrations of 1.1 and 0.6 microM, respectively. Again, when the intravesicular H+ concentration was reduced by inclusion of imidazole (2.5 mM), pantoprazole (20 and 60 microM) did not reduce the remaining intravesicular proton concentration, whereas omeprazole (10 and 30 microM) did. Both drugs inhibited, with similar potency, papain activity at pH 3.0 and inactivated the enzyme in a similar time-dependent manner; at pH 5.0 omeprazole (IC50 17 microM) was more potent than pantoprazole (IC50 37 microM) and enzyme inhibition was faster than with pantoprazole. These results indicate that pantoprazole is a potent inhibitor of H+/K(+)-ATPase under highly acidic conditions and that it is more stable than omeprazole at a slightly acidic pH such as pH 5.0[3].
For non-cellular enzyme assays, pantoprazole’s inhibition of H⁺/K⁺-ATPase can be evaluated using purified enzyme preparations or gastric membrane vesicles in cell-free systems. The enzyme activity is measured by monitoring ATP hydrolysis or proton transport. IC50 values are determined by incubating varying concentrations of pantoprazole with the enzyme under acidic conditions that promote its activation. |
| Cell Assay |
Murine EMT-6 and human MCF-7 cells were treated with pantoprazole to evaluate changes in endosomal pH using fluorescence spectroscopy, and uptake of doxorubicin using flow cytometry. Effects of pantoprazole on tissue penetration of doxorubicin were evaluated in multilayered cell cultures (MCC). Pantoprazole (>200 μmol/L) increased endosomal pH in cells, and also increased nuclear uptake of doxorubicin. Pretreatment with pantoprazole increased tissue penetration of doxorubicin in MCCs [1].
In vitro cellular assays for pantoprazole involve treating gastric parietal cells or cancer cell lines with the compound. In parietal cells, the inhibition of acid production is measured using pH-sensitive dyes or by quantifying proton secretion. In cancer cells, effects on proliferation (MTT assay), apoptosis (flow cytometry), and HIF-1α expression (Western blot) are assessed. |
| Animal Protocol |
Animal/Disease Models: Mice bearing MCF-7 or A431 xenografts [1]
Doses: 200 mg/kg Route of Administration: IP; once weekly for 3 weeks; alone or in combination with doxorubicin (6 mg/kg iv) First 2 hour Experimental Results: The growth delay of MCF-7 xenografts with doxorubicin was even greater compared to the single dose combination. A single dose of doxorubicin Dramatically increased tumor growth delay. alone had no effect on growth delay. In vivo animal experiments for pantoprazole involve administering the compound to animal models of gastric acid hypersecretion or ulcer disease. Efficacy is assessed by measuring gastric acid output, ulcer formation, and healing. Pharmacokinetic and toxicological studies are conducted in rodents and other species to evaluate absorption, distribution, metabolism, excretion, and safety. |
| ADME/Pharmacokinetics |
Pantoprazole Sodium has a molecular formula of C₁₆H₁₅F₂N₃O₄S•Na. It is administered orally or intravenously. After oral administration, it is protonated in the acidic environment of the parietal cell canaliculus, converting to the active form that binds covalently to H⁺/K⁺-ATPase. The compound has a relatively slow onset of action but provides prolonged acid suppression.
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation When a mother takes 40 mg of pantoprazole daily, the drug concentration in breast milk is low and is not expected to have any adverse effects on breastfed infants. ◉ Effects on Breastfed Infants As of the revision date, no relevant published information was found. ◉ Effects on Lactation and Breast Milk A retrospective US claims database study found an increased risk of gynecomastia in users of proton pump inhibitors. A review article reported that a search of the European Pharmacovigilance Center database found 48 cases of gynecomastia, 3 cases of galactorrhea, 14 cases of breast pain, and 4 cases of breast enlargement associated with pantoprazole. A search of the World Health Organization Global Pharmacovigilance Database found 97 cases of gynecomastia, 13 cases of galactorrhea, 35 cases of breast pain, and 16 cases of breast enlargement associated with pantoprazole. Pantoprazole is generally well-tolerated. Common side effects include headache, diarrhea, and nausea. Long-term use may be associated with increased risk of bone fractures, vitamin B12 deficiency, and hypomagnesemia. The compound may also increase the risk of Clostridium difficile infection and gastric neoplasia with prolonged use. It should be used at the lowest effective dose for the shortest duration. |
| References |
|
| Additional Infomation |
Pantoprazole sodium is an organosodium salt. It is an EC 3.6.3.10 (H(+)/K(+) exchange ATPase) inhibitor and an anti-ulcer agent. It contains the pantoprazole (1-) structure. Pantoprazole sodium is a sodium salt form of substituted benzimidazole with proton pump inhibitor activity. Pantoprazole is a lipophilic weak base that crosses the parietal cell membrane into the acidic parietal tubules, where it is protonated to generate the active metabolite sulfinamide. The sulfinamide forms irreversible covalent bonds with two sites on the H+/K+-ATPase on the gastric parietal cells, thereby inhibiting basal and stimulant gastric acid secretion. 2-Pyridylmethylsulfinylbenzimidazole proton pump inhibitor, used to treat gastroesophageal reflux and peptic ulcers. See also: Pantoprazole (containing the active ingredient).
Drug Indications For short-term treatment of reflux symptoms in adults (e.g., heartburn, acid reflux). Pantoprazole Sodium is approved for the treatment of acid-related disorders including GERD, erosive esophagitis, and Zollinger-Ellison syndrome. It is available under various brand names. The compound’s irreversible inhibition of H⁺/K⁺-ATPase provides effective acid suppression. Research has also explored its potential chemosensitizing effects in cancer therapy. |
| Molecular Formula |
C16H14F2N3NAO4S
|
|---|---|
| Molecular Weight |
405.35
|
| Exact Mass |
405.057
|
| Elemental Analysis |
C, 47.41; H, 3.48; F, 9.37; N, 10.37; Na, 5.67; O, 15.79; S, 7.91
|
| CAS # |
138786-67-1
|
| Related CAS # |
Pantoprazole;102625-70-7;Pantoprazole sodium hydrate;164579-32-2;S-Pantoprazole sodium trihydrate;1416988-58-3
|
| PubChem CID |
15008962
|
| Appearance |
Typically exists as white to off-white solids at room temperature
|
| Boiling Point |
586.9ºC at 760 mmHg
|
| Melting Point |
199-202ºC
|
| Flash Point |
308.7ºC
|
| LogP |
3.535
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
27
|
| Complexity |
497
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C([H])([H])C1C(=C(C([H])=C([H])N=1)OC([H])([H])[H])OC([H])([H])[H])(C1=NC2C([H])=C(C([H])=C([H])C=2[N-]1)OC([H])(F)F)=O.[Na+]
|
| InChi Key |
YNWDKZIIWCEDEE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14F2N3O4S.Na/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3/q-1+1
|
| Chemical Name |
sodium5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
|
| Synonyms |
BY1023; SKF96022; Protonix; BY 1023; BY-1023; SKF 96022; SKF-96022; Pantoloc; Controloc; Pantecta; Zurcal; Protonix; SK and F-96022; SKF-96022
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~246.70 mM)
H2O : ~3.85 mg/mL (~9.50 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.17 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.17 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.17 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 8.33 mg/mL (20.55 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4670 mL | 12.3350 mL | 24.6700 mL | |
| 5 mM | 0.4934 mL | 2.4670 mL | 4.9340 mL | |
| 10 mM | 0.2467 mL | 1.2335 mL | 2.4670 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA